Section 4 – Disruptions / Hypoxic-Ischemic Injury
Section 4 Disruptions / Hypoxic-Ischemic Injury Cellular Responses Chapter 29 Neuronal Death Marc Del Bigio Neuron Death in the Developing Brain The idea that loss of neurons could be associated…
Neuroanatomic Site Development
Neuroanatomic Site Development Chapter 19 Human Nervous System Development: Embryonic and Early Fetal Events Marc Del Bigio In human pregnancy, the developing individual is considered to be an embryo until…
Section 6 – Perinatal Neurooncology
Section 6 Perinatal Neurooncology Chapter 48 Congenital and Perinatal Brain Tumors Sanda Alexandrescu Introduction Central nervous system (CNS) tumors are the second most common neoplasms in the pediatric population, being…
Section 3 – Stillbirth
Section 3 Stillbirth Autolysis, Artifacts, and Stillbirths Chapter 27 Autolysis and Artifacts Marc Del Bigio The word artifact is derived from the Latin words arte (“by skill”) and factum (“thing…
Prosection Techniques
Prosection Techniques Chapter 9 Brain Prosection Marc Del Bigio Before the Autopsy The ability to conduct an autopsy safely and competently must be established. Guidelines for doing so have been…
Tissue Selection
Tissue Selection Chapter 13 Selection of Brain Areas for Microscopic Examination Mirna Lechpammer and Rebecca Folkerth Introduction Tissue specimens collected during the autopsy are largely used for diagnostic purposes; however,…
Approach to Autopsy of the Perinatal Nervous System
Approach to Autopsy of the Perinatal Nervous System Chapter 1 Clinical Considerations Rebecca Folkerth The initial steps in the process of perinatal nervous system evaluation, namely the planning of the…
Chapter 4 – Autopsy and Research Consent
Abstract Legal jurisdictions in most Western countries have legislation that allows acoroner or medical examiner to mandate an autopsy without consent by the next of kin in certain situations (e.g.,…
Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
Objective In December 2020, 2 lipid nanoparticle-formulated, nucleoside-modified messenger RNA–based vaccines received emergency use authorization by the US Food and Drug Administration, after their trials demonstrated 94% to 95% efficacy…
